Description
Hope it will be useful for you guys.
Summer Training
at
SUN PHARMACEUTICAL INDUSTRIES
LTD.
Silvassa
Guided By
Dr. R.S.Shah
Prepared By
Nirav Kariya
Praya Si!h
Neha Si!hal
GIDC Ra""u Shr#$$ R#$$el I!s%i%u%e &$
Ma!ae'e!% S%udies
(api
INDE)
Sr.No. Topic
1 Acknowledgment
2 Company Profile
3 Plant Location
4 Plant Layout
5 Process Layout
6 Production
7 uality control
! "uman #esource $epartment
% &inance'Account $epartment
1( )anagement *nformation +ystem
11 )arketing $epartment
A*+!#,led'e!%
Da%e - ./012012
3e are very %ha!+$ul %# GIDC Ra""u Shr#$$ R#$$el I!s%i%u%e &$ Ma!ae'e!%
S%udies a!d #ur Dire*%#r Dr. R.S.Shah $#r pr#vidi! us a ,#!der$ul su''er
%rai!i! a% Su! Phar'a*eu%i*al i!dus%ries L%d.4 Silvassa.
3e als# %ha!+$ul %# Mr.Pra+ash Raval 5Pla!% Head6 a!d Mr.Pri%e! Nair $#r uidi!
us i! vari#us aspe*%s a!d pr#vidi! us deep pra*%i*al +!#,lede reardi!
'a!ae'e!%. 3e als# %ha!+$ul %# all %he s%a$$ 'e'7ers #$ Su! Phar'a*eu%i*al
I!dus%ries L%d. 8#r spe!di! %heir pre*i#us %i'e i! uidi! us $#r #ur pr#"e*%.
Reards4
Nirav Kariya
Praya Si!h
Neha Si!hal
C#'pa!y Pr#$ile
Sun pharmaceuticals industries ltd. specialty is pharmaceuticals and active pharmaceutical
ingredients. Their brands are prescribed in chronic therapy areas like cardiology,
psychiatry, neurology, gastroenterology, diabetology and respiratory.
They have the same drive for growth that marked our early days. Sun Pharma came into
existence as a startup with just 5 products in !!". #n the time since, they have crossed
several milestones to emerge as a leading pharma company in #ndia, a rank that we have
now been at for more than 5 years. $#%S&'() (etail Store *udit, %arch +,,-.
They have reached leadership in each of the therapy areas that they operate in, and are
rated among the leading companies by key customers. Strengthening market share and
keeping this customer focus remains a high priority area for the company.
#n the post !!- years, we have used a combination of internal growth and ac/uisitions to
drive growth0 important mergers were those of the 1S, 2etroit based 3araco Pharma 4abs
and that of the plant at 5alol which is now 16%5(* and 1S72* approved.
HISTORY
Sun Pharma began in !8" with just 5 products to treat psychiatry ailments. Sales were
initially limited to + states & 9est :engal and :ihar. Sales were rolled out nationally in !85.
Products that are used in cardiology were introduced in !8;, and %onotrate, one of the
first products launched at that time has since become one of our largest selling products.
#mportant products in 3ardiology were then added0 several of these were introduced for the
first time in #ndia.
(eali<ing the fact that research is a critical growth driver, they established their research
center SP*(3 in !!" and this created a base of strong product and process development
skills.
Sun Pharma was listed on the main stock exchanges in #ndia in !!=0 and the (s. 55 crore
issue of a (s. , face value e/uity share at a premium of (s. =,>& was oversubscribed 55
times. The minimum +5? that was re/uired under the regulations then for listing was
offered to the public, the owner family continues to hold a majority stake in Sun Pharma.
They used this money to build a )reenfield site for *P# manufacture, as well as for
ac/uisitions. 7or the ac/uisitions, typically companies or assets that could be turned
around and brought on track were identified.
Their first *P# manufacturing plant was built in Panoli in !!5, for access to high /uality
actives ahead of competition, and to tap the vast international opportunity for specialty
*P#s.
*nother *P# plant i.e. *hmednagar plant, was ac/uired from the multinational 6noll
Pharmaceuticals in !!-, and upgraded for approvals from regulated markets, with
substantial capacity addition over the years. This was the first of several sensibly priced
ac/uisitions, each of which would bring important parts to the long&term strategy.
:y !!;, Sun Pharma@s head/uarter was shifted to %umbai, the commercial capital of the
country. They began on the first of their international ac/uisitions with an initial A;.5 million
investment in 3araco Pharm 4abs, 2etroit. :y +,,,, we had completed 8 ac/uisitions, each
such move adding new therapy areas or offering an entry to important international markets.
* new research center was set up in %umbai for generic product development for the 1S
market. #n #ndia, as new therapy areas were entered into post ac/uisition0 customer
attention, product selection and focused marketing helped us gain a foothold in areas like
orthopedics, gynecology, oncology, etc. 7rom a ranking at "8
th
in !!=, by +,,, we were
ranked 5
th
with a leadership in 8 of the therapy areas that we are present in. The year
+,,, was the year of turnaround at the 1S subsidiary, 3araco, as it began to receive
approvals after successful inspection by the 1S72*. #n 2ecember +,,=, a research center
spread over - acres was inaugurated by the President of #ndia, with special lab space for
drug discovery and innovation.
Milestones
.9:;
Sun Pharma begins operations in 6olkata with 5 psychiatry & based products, first with
+ people and then with a , & employee team. Bear turnover & (s. million. 9ithin a
year, the marketing effort is expanded to cover all eastern states. * compact
manufacturing facility for tablets>capsules is set up at Capi.
.9:/
*dministrative office is set up in %umbai. 3ustomer coverage extends to select cities in
9estern #ndia.
.9:2
%arketing operations are rolled out nation&wide.
.9::
9ith the launch of the brands %onotrate and *ngi<em, the first few cardiology products
are launched. 9e feature for the first time in a market audit by the prescription tracking
company, '() at rank ,;
th
with ,.? market share.
.9:9
The corporate office is shifted to :aroda, in the western state of )ujarat. Products used
in gastroenterology are introduced. Dxports to neighbouring countries begin.
.99.
3onstruction begins at the first research center SP*(3 $Sun Pharma *dvanced
(esearch center., with =-,,,, s/ ft of research space, and investments of almost the
si<e of that yearEs profits. The companyEs turnover is (s. !.;= crore, and market rank is
;,
th
.
.99;
SP*(3, the first research center, is inaugurated by 5is Dxcellency Shri 6. (.
Farayanan, the Cice President of #ndia. *n office is begun in %oscow. Products are
now registered across , markets.
.99<
*fter an #P' in 'ctober, we are listed on the major stock exchanges in #ndia. The
offering is oversubscribed 55 times. * dosage form plant at Silvassa starts production.
%ajor expansion at the plant in Capi is completed. 7or the first time, a brand from the
company, %onotrate, features among the top +5, pharma brands in the #ndian market.
Dxperimenting with a focused marketing approach, a separate division, Synergy, is
carved out to market Psychiatry> Feurology products.
.99=
Sun Pharma first *P# plant at Panoli starts production.
* new division, *<tec, now renamed *<ura, is begun for cardiology products, with a
further reallocation of products across divisions. #nca, a new division to market critical
care medication to intensive care units begins operations. #nternational marketing is
strengthened with offices in 1kraine and :elarus.
.99/
*n *P#&manufacturing unit at *hmednagar, the first of the Sun Pharma ac/uisitions, is
bought from 6noll Pharma,
.992
7irst international ac/uisition of Sun Pharma. *s part of a technology&for&e/uity
agreement, a stake is ac/uired in a generic dosage form manufacturer0 the 2etroit&
based 3araco Pharm 4abs.
T2P4, a company with an extensive product offering $oncology, fertility, anesthesiology,
pain management. is merged with Sun Pharma,
.99:
* basket of brands, which include several in the respiratory>asthma area, are ac/uired
from Fatco Pharma. Sun PharmaEs new formulation plant at Silvassa commences
operations,
.999
(ank moves within the top , in the domestic market. 7or a /uick entry in
ophthalmology, %ilmet 4abs is merged into Sun Pharma.
>111
(anked 5th among all companies in the domestic market on a monthly basis. Pradeep
2rug company, a 3hennai based *P# manufacturer is merged with Sun Pharma.
>11.
* new formulation plant is built in 2arda. This new plant is spread over a 5&acre site with
built up area of +,,,,,&s/. ft. and has been designed and built to comply with
international regulatory re/uirements, such as the 16%5(* and 1S72*.
The erstwhile T2P4 division is renamed Spectra. * new division, *rian, targeting
cardiologists>physicians and diabetologists, is launched.
>11>
7orbes )lobal ranks Sun Pharma in the list of best small +,, companies for +,,+
$turnover less than A5,, million..
Sun Pharma is selected as the best company by Dxpress Pharma Pulse, for overall
performance for +,,+ $in the category * & market share over +.5?.. = manufacturing sites
win the prestigious #2%* awards.
9ork begins on a new (G2 center in %umbai, with 5,,,,, s/. ft. floor area for projects
aimed at the Forth *merican and Duropean markets.
>11;
7orbes )lobal ranks Sun Pharma in the list of the best small +,, companies for +,,"
$turnover less than A5,,million..
Sun Pharma is rated amongst the best&managed companies for +,," across all sectors.
>11<
Sun Pharma ac/uires common stock and options from + large shareholders of 3araco,
increasing stake to over -,? from ==? at a total outlay of about A=+ million.
3onstruction at a formulation manufacturing site at Hammu is completed.
7irst joint venture manufacturing unit, in 2haka, :angladesh is commissioned. This
modern site is spread over +5,,,, s/. ft.
>11=
Sun Pharma buys a plant in :ryan, 'hio, 1S and the business of #3F, 5ungary from
Caleant Pharma.
Sun Pharma ac/uires the intellectual property and assets of *ble 4abs from the 1S
2istrict :ankruptcy court in Few Hersey in 2ecember +,,5.
2ilip Shanghvi, the 3%2, receives the DGB Dntrepreneur of the Bear award in healthcare
and life sciences for +,,5.
Sun Pharma is selected by 7orbes amongst the best +,, companies $sales less than
1S2 billion. in *sia. This is the fourth time in 5 years that the company has been
selected.
The %ally a% %he e!d #$ >11=
? 5 manufacturing plants in " continents
? 5,,, employees
? + 9orld class research centers
? :rand selling in markets worldwide
? * growing presence in the 1S generic market
? #ncreasing research investments
? =,? of sales from international markets
GROUP COMPANIES
Cara*# Phar'a*eu%i*al La7#ra%#ries
:ased in 2etroit, %ichigan, 3araco develops and manufactures generic pharmaceuticals
and markets them throughout the 1nited States. The corporationEs present portfolio
consists of a number of products in various strengths and package si<es. The
corporationEs drugs relates to a variety of therapeutic segments.
3aracoEs manufacturing facility and executive offices were constructed in !!,
Su! Phar'a*eu%i*al I!dus%ries I!*.
Sun Pharmaceutical #ndustries #nc is a %ichigan 3orporation and a wholly owned
subsidiary of Sun Pharmaceutical #ndustries 4td, #ndia. The company distributes
pharmaceutical products throughout the 1nited States and around the world.
#n the second half of +,,=, Sun Pharma ac/uired the trademarks, manufacturing know&
how and other intellectual property of certain pharmaceutical products from 9omenEs
7irst 5ealth care, #nc,
#n 2ecember +,,=, the company entered into a manufacturing and supply agreement
with 3araco Pharm 4abs, under the terms of this agreement, 3araco manufactures and
supplies the products to the company. #n Hanuary +,,5, the company entered into a
distribution and sale agreement with 3araco. 1nder the agreement, 3araco distributes
and sells these products using its business organi<ation, management personnel, and
distribution set up.
Su! Phar'a*eu%i*al 5Ba!ladesh6
Sun Pharmaceutical $:angladesh. is a private limited company incorporated in %arch
+,, under the 3ompanies *ct !!=. This company was formed jointly with Sun
Pharma, 3ity 'verseas 4td, a company incorporated in :angladesh and Sun Pharma
)lobal #nc, a company incorporated under the laws of the :ritish Cirgin #slands. The
company began commercial operations in 'ctober +,,=. The company owns and
operates a pharmaceutical factory and makes pharmaceutical products that are sold in
the local market.
ACQUISITIONS
? Tamil Fadu 2adha Pharmaceuticals
*c/uisition, !!;
? )ujarat 4yka 'rganics 4td.
D/uity stake !!-, %erged !!!
? %H Pharmaceuticals 4td.
D/uity stake, !!-0 merged with Sun Pharma in +,,+&,"
? 3araco
Subsidiary&initial e/uity stake !!;, incremental stake increases !!;&+,,",
larger stake buyout +,,=
? :rands from Fatco Pharma
:rand buyout, !!8
? %ilmet 4abs
*c/uisition, !!!
? Pradeep 2rug 3ompany 4td
*c/uisition, +,,,
? Phlox Pharma
%erged +,,=
? Fiche brands purchased from 9omenEs 7irst 5ealth care
+,,=
?
? #3F, 5ungary $+,,5. and a manufacturing plant in :ryan, 'hio
+,,5
? *ble 4abs
*ssets only, 2ecember +,,5
MANUFACTURING
9ith world class technology and a team of strong professionals, we have built sites and
systems that meet the most stringent international manufacturing standards. Dxpert
/uality teams ensure that systems and processes remain in compliance with the latest
standards. * number of our plants hold approvals from the 1S72* and the 16 %5(*.
*P#s and 2osage forms are made in 5 sites across #ndia, 1S, 5ungary and
:angladesh.
FORMULATION
Sun PharmaEs specialty product range features solid oral dosage forms $tablets,
capsules., injections, nasal sprays, aerosols, dry powder inhalers, ophthalmic
preparations, creams and ointments as well as technically complex preparations like
melt tabs, liposome based products, depot preparations and time release > controlled
release preparations.
API
Sun Pharma make specialty *P# at large world class sites with multi reaction and multi
capacity flexibility. #n all, the total reaction capacity is over ++, 64>year.
5ungarian plant is part of a recent ac/uisition, that of the company #3F 5ungary,
formerly known as *lkaloida. This is one of the few sites worldwide authori<ed to make
controlled substance *P#s.
Sun PharmaEs plants at Panoli and *hmednagar.
*ll its plants are large, well&designed and comply with international re/uirements.
?UALIT@ P&LIC@
Sun Pharma have put in place the infrastructure and procedures to support a stringent
/uality policy. *ll their systems are well documented and are implemented by an expert
trained staff with a line of reporting that is independent of manufacturing.
They are committed to ensure that every product we manufacture and distribute meets
with and conforms over its shelf life to internationally accepted standards of /uality,
purity, efficacy and safety.
*t each manufacturing site, the latest analytical instruments and tightly monitored /uality
assurance and /uality control systems ensures consistent /uality of Sun Pharma
products.
The /uality team at each manufacturing site is guided by a 3orporate Iuality 1nit $3I1..
This 3I1 has members from /uality assurance, /uality engineering, /uality control, and
regulatory affairs. 3I1 regularly updates location&based /uality representatives on new
regulatory practices and monitors the /uality of documentation in order to comply with
changing international re/uirements.
EN(IR&NMENTAL P&LIC@
%anufacturingJ 3onsistently producing to the worldEs re/uirements.
3oncern for the environment and safety.
Dach of our manufacturing sites is fully e/uipped with facilities to handle waste and
minimi<e environmental contamination. *t Sun Pharma, a concern for safety and the
environment is part of our plans right from the drawing board. 9e pay close attention to
preventing and reducing pollution, avoiding accidents and conserving resources.
Research and Development: Building a strong research base
*t Sun Pharma, we are committed to world class research to develop the latest
medicines and bring them to market for patient benefit at a reasonable cost. 'ur (G2
efforts help us develop a product basket, including products that have complex
technologies, for the international markets. 7ocused development in defined areas and
interest in applying innovative technologies are key to our efforts.
Sun Pharma first research center, Sun Pharma *dvanced (esearch 3enter $SP*(3.,
was set up in !!" in :aroda in the western state of )ujarat in #ndia. The work done
here was instrumental for the rapid growth at Sun Pharma. Starting from a small base,
the infrastructure at this initially "+,,,, s/ ft research center was used to streamline
product development to bring to market on an average ", formulations and 8&, new
*P# every year.
#n +,,=, a new research campus with areas for process > product development as well
as drug discovery and delivery systems went on stream in :aroda. 5is Dxcellency, 2r. *
P H *bdul 6alam, the 5on. President of #ndia, formally inaugurated this research center
in a glittering ceremony in 2ecember +,,=.
This -&acre campus with +5,,,,, s/ ft research area offers space for world&class
pharmaceutical research0 both for complex generics and new&to&the&world drug
discovery.
#n the first phase of innovation, a drug discovery initiative is taking shape in " specific
therapy areas and across = drug delivery system platforms. These projects, on
successful completion, can offer strong potential across international markets. 5ence
these call for focus. The intellectual property that we build from these projects can one
day earn revenue streams globally. #n view of this opportunity and recogni<ing that
innovation is a uni/ue business & #nnovative (G2 is proposed to be demerged into a
separate company.
* second research center was set up in !!; in %umbai to develop generics for the
developed markets. This center has developed products for 3araco & most of the
products that are marketed by our 1S subsidiary were developed by this team.
The current research commitment is between &+? of the companyEs turnover and
weEve put in a total of (s. -,,, million for research since !!". Their approach to
research has been incremental starting with the simple and moving on to the more
complex. Sun Pharma began with simpler dosage forms, and then moved on to novel
drug delivery systems and complex *P#. *cross areas, =+ patents have been received
and another =++ patents are awaited. Dvery year, Sun Pharma typically bring about =,
new products to the #ndian market, scale up +, *P#, develop and file for +, plus *F2*s
for the 1S and 8&, 2%7s for 1S > Durope.
P4*FT 4'3*T#'F
Location and Surroundings
L#*a%i#!
? Pharmaceutical formulation plant should not be in a chemical <one.
? Feighbouring unit should not generate any air, water or noise pollution, which can
affect the man, material, machinery and the product /uality of the formulation plant.
Surr#u!di!s
? Protection is re/uired against the entry of insects, rodents and other pests0 in
particular, the stray dogs and cats must be prevented.
? The surroundings must always present a clean and good appearance0 obvious signs
of neglect or lack of maintenance such as broken windows, peeling paint,
accumulation of debris, untended gardens and so on, give rise to serious doubts about
good manufacturing practices.
? :uilding should have ade/uate garden, but not too near to the walls of the main
building.
? Security office should have visibility from all sides.
? Provision of instructions $no smoking board, etc.
? 4ay&out of premises.
? *larm for any emergency
? 7irst aid box
? 2isplay of contact number of head of different authority $factory inspector, police, fire
brigade, hospital, collector, plant head, etc.
? Separate administration block
? 1tility block $generator house, air compressor house, boiler house.
? Solvent storage
? DTP plant
? Scrap yard
? Transformer house should be provided
? 1nderground tank should be avoided and if re/uired than it should be constructed of
round shape and the top of the tank should be at road level, so that fire brigade van
can stand on it.
? Street shoes cleaning facility specially for monsoon season so that mud will not come
with shoes in area.
? *de/uate parking facility for vehicles.
? Storage tank for diesel, etc at safe place.
*ny building used in manufacturing process, packing or holding of a drug product, shall
be of J
? Suitable si<e
? 3onstruction
? 4ocation to facilitateJ
?
• 3leaning
• %aintenance
• Proper operation
:uilding should have ade/uate space for the placement of e/uipment and materials to
prevent0
? %ix&ups
? 3ontamination
? The design should permit effective communication and supervision.
? 2esign of the building should be such that it provides unidirectional flow of
materials to reduce any chances of confusion and contamination.
? 3onventional designs feature such as a corridor running along the length of the
building with rooms, cubicles, halls and other areas opening in to it.
? The merit of this design is the isolation of manufacturing operations from non&
related activities and confinement of the movement of people to a common
passage.
1nit processes for a product should be carried out in the areas physically segregated
from one another with the result that a batch in process moves from one area to another
through hatch provided between adjacent rooms to facilitate the movement of in&process
material in controlled $temperature, humidity and pressure differential. area and will
never enter into corridor.
PLA-. LA/01.
4ayout of the building should be off vertical structure for gravity feeding in which the
material movement is in unidirectional flow and which reduces material loading and
unloading.
The above mentioned design consists of the following featuresJ
? (aw material store, dispensing booth, staging area for storage of dispensed (.%.,
sifting, milling operation with washing facility should be at second floor of the building.
? Sifting room is designed as one e/uipment one area with independent dust collector
unit and air handling system with terminal 5DP* filter and S.S. stand for utensil with
hanger for gloves is re/uired in the area
? 'ne S.S. connecting pipe with sanitary fitting can be attached with bottom discharge of
#P3 and charging point of (%) keeping lid closed
? Sifted material collected in #P3 is directly charged in to (%).
? Similarly milling operation can be done in independent area and facility is to be
provided as with sifter room.
? *rea for granulation, blending, '5( and Iuality 3ontrol laboratory should be at first
floor.
? (%) room should have separate *.5.1. and facility to run mercury lamp and sodium
vapour lamp.
? 1tilities like potable water, steam, non&lubricated area, purified water and hot air should
be provided with drain point facility.
? The material flows from sifting and milling area to (%) through raw material transfer
pipe.
? 7rom (%) to blending the material moves through hatch provided between adjacent
rooms.
? Powder transfer system using vacuum as a principle is acceptable to avoid human
touch in blending area.
? The lubricated granules are to be transferred from '5( $over head room. located at
the first floor in front of granulation area by the raw material transfer pipe to the
compression machine located below the '5(.
Process Layout
PRODUCTION
Were House
1nder warehouse there are three departments. They areJ
(aw %aterial Store $(.%.S.
Purchase %aterial Store $P.%.S.
nded Store (oom $:.S.(.
Ra, Ma%erial S%#re
The main work of (.%.S is to dispense raw material to production department. The
following areas are covered in this department areJ
. 4oading and unloading platform
+. Iuarantine area
". Sampling area
=. 2ispensing area
5. (ejected area
-. 3old storage facility
;. Potent drug storage
8. (eceiving bay
Pa*+ai! Ma%erial S%#re
The main work of this department is to dispense packing material to packing
department..
The following function are being carried in this department areJ
. To receive packing material
+. To label received material
". To arrange for labeling of material
=. To store material as per status of material
5. To dispense> issue material
-. To maintain /uality of store material
;. To maintain physical stocks as per D(P systemEs stock
8. To identify shortage and coordinate for procurement as per production plan.
B#!ded S%#re R##'
The main work of this department is to receipt, handling, storage of finished goods and
dispatch of finished goods.
The main function of this department areJ
? (eceipt of finished goods from packing
? %aintaining documents related to excise
? %onitoring of modat of input and P4*
? 4egal formality and documentation with excise authority
? %aintaining of finished goods stock and documentation
? 2ispatch and documentation
? %aintaining stock statement Cs. physical stock
Pr#du*%i#! Depar%'e!% C#!sis%s &$
? )ranulation
? 3ompression
? 7
> 3oating
? 2P#> 3apsule
? Packing
Granulation
)ranulation is a process of getting granules from fine powder or preferably be reduce
to the same particles si<e, since particles of different si<e will have a tendency to get
layered during mixing.
Gra!ula%i#! is d#!e 7y
. 9et )ranulation
+. 2ry )ranulation
EAuip'e!% used are
? Cibro Sifter
? 3lit mill
? (apid %ixer )ranulator
? 7luidi<ed :ed 2ryer
? Steam Hacketed 6ettle
? :lender
Pr#*ess
S#7T#F) *F2 %#44#F)
23. 4#A-1LA.*0-
5 )*6*-47
)*LL*-4 0& +L14+
$#/ 4#A-1LA.*0-
&*-AL 8L3-$*-4
5L18#*CA.*-47
Compression
#t is carried out after granulation.
3ompression is a property of forming stable mass when press is applied.
3ompression is achieved by taking granules in a die and compressing them between a
set of two punches.
EAuip'e!%s-
(otary tablet compression machine. There are six machines of compression in sun
pharmaceutical
exJ "5 Station machine
"; station machine
=5 station machine
Pr#*ess #$ *#'pressi#!
4oad granules in hopper$top of machine.
*djust machine for
? 3ompression weight
? 5ardness
? Thickness
? 2isintegration time
K 2iscard initial + rounds of tablet
(est all the tablets are kept for inspection
$to find out and remove defective tablets,
tablet inspection machine is used..
FBP/ Coating
3oating is done to improve elegance and organoleptic /uality.
%ainly coating is done toJ
. %ask the taste, color and odour of drugs.
+. To provide physical and chemical protection for drugs.
". To control the release of drug.
=. To protect the drug from gastric environment of stomach with acid resistance
enteric coating.
5. To improve particular aligance by use of special color.
DPI/CAPSULE
3apsule are the solid dosage form in which the drug substance are enclosed within
either a hard or soft soluble shell usually forms from gelatin.
QUALITY CONTROL
Iuality dept. is a centrali<ed department of Sun pharma. #t consists of two sub dept.J
? Iuality 3ontrol
? Iuality *ssurance
Iuality control looks upon /uality of raw materials and formulation whereas /uality
assurance looks upon dispatch material.
'ver all in /uality dept. there are about =, staff members and one senior manager.
*mong =, members +; is in I3 dept. and " in I* dept.
Ma!ae'e!% Pla!!i!
*ll members in this dept are been divided according to the department of sun pharma,
for e.g. (%S dept., P%S dept., etc. Dmployees work according to their job
responsibility. Dvery pharma material that enters or exit from sun pharma is being
checked and approved by I3 and I* dept. for e.g. (aw material enter in plant is
being first sampled by I3 and then approved for further process. Similarly for other
departments the procedure carried same and hence, each and every employee of I3
and I* is being divided according departments each and every procedure followed
between the dept. is being controlled and coordinated by D(P system.
To achieve the objective I3 department functions as follows
? To plan and manage all the, activity of I3.
? To coordinate with manufacturing department in controlling their process and
products at every stage of production to meet the established specification.
? To coordinate for development of specification analytical procedure in
coordination with I* dept. and (G2 department.
? To review the ade/uacy and relevance of specification and analytical procedure
in coordination with I* and (G2.
? To coordinate technical audit of I3 lab.
? To determine the analytical /uality system are yielding the highest /uality
information and to ensure the calibration of instruments and servicing as per
schedule.
"1)A- #3+01#C3
$3PA#.)3-.
#t consists of two sub departmentsJ
? Personal department
? *dministrative department
PERSONAL DEPARTMENT
This department consists of process like training and development, recruitment and
selection, performance appraisal, policy implementation, compensation, etc.
Re*rui%'e!% a!d sele*%i#!
The procedure of recruitment and selection is being carried out as followJ
#f there is any new vacancy or vacant position a %P( 7orm i.e. manpower re/uisition
form is being filled by department head and then sends to head office in %umbai to get
approval of it. #f %P( is being approved than as the profile re/uirement an
advertisement is issued. *nd the se/uence goes as followJ
? Pri#r &$$er
? *pplication > resume receive
? 3all letter for preliminary interview
? Personal information form filling on the day of interview
? (eturn test on respective subjects
? Preliminary interview assessment sheet filled by panel member
? 3all letter for final interview
? 7inal interview assessment sheet filled by plant head
? 2ocument
• Proof of date of birth
• %ark sheet of post graduation, graduation, +
th
, !
th
and additional
/ualification if any.
#f the person being selected his documents is send to head office %umbai and on the
basis that a joining offer letter is being issued from head office %umbai.
? Duri! &$$er
? %edical report
? Signing offer letter
? Day #$ "#i!i!
? (elieving letter from previous employer > copy of resignation letter
? 9ork experience certificate
? 7orm + i.e. )ratuity form $photo copy.
? 7orm f i.e. provident fund
? 5(#S 7orm
? *ppointment letter
? #n the course of employment
? 4etter of probation
? 4etter of conformation
? #ncrement letter
? 'ffice order
*t last the employee is being added to D(P system and date of master entry and pay
roll entry in D(P is being recorded. *nd the employee is being provided with an intra
mail e&mail #d.
Training and developmentJ
Training in sun pharma is being carried out according to the procedure and format
mention in S'P $Standard 'perating Procedure..
Type #$ %rai!i! *arried #u% a% Su! phar'a is
? Dxternal Training
? 3lass room Training
? 'n the job training
? induction training
E)TERNAL TRAINING
#n external training a person is being nominated as per the information from various
agencies on consultation department head as per the information. The necessary
arrangement to attain the external training is being made as per the re/uirement and
there after training is being maintained for e.g. 'n ++
nd
of Hune +,,; %r. Sujoy
3haudhry has been invited to give training on the topic assertiveness and team
building.
CLASSR&&M TRAINING
* training schedule for the entire department is being prepared and circulated to the
department head. #f the schedule is finali<ed then training aids are being prepared and
training program is being conducted. There after training record is being maintained.
'n the basis of classroom training a evaluation is done for competence and
effectiveness.
&N THE B&B TRAINING
#n this training a competent person organi<es on job training to concern person and
demonstrate the actual operation. This training is being given by the department head
to staff members or supervisors or even by the consulted to whole department.
INDUCTI&N TRAINING
This training is being carried out for new employee on the first day of joining. There is
an induction form which is being filled by new employee which contains sufficient detail
about him. There after he has been introduced to each an every department head and
explain a brief profile of Sun Pharma.
P&LIC@ IMPLEMENTATI&N
There are several policies designed by 5.'. 9hich has been commonly followed
by all the plants of Sun Pharmaceutical #ndustries 4td. Some of the policies followed in
SP#4 are as follows..
? P'4#3B 'F 4D*CD
? 1SDS '7 3'%P*FB P('213T
? P'4#3B 'F 3*( 4'*F T' SDF#'( %*F*)D( *F2 2DP1TB
%*F*)D(
? P'4#3B 'F TD4DP5'FD 7*3#4#TB 7'( %*F*)D(
? P'4#3B 'F T(*FSP'(T*T#'F 7'( ST*77
? PD(S'F*4 *33#2DFT #FS1(DF3D P'4#3B
? P'4#3B 'F T'1( *2C*F3D
? P'4#3B 'F 5'SP#T*4#L*T#'F
FD7#TS
? P'4#3B 'F 2(DSS (D#%:1(DSD%DFTS 7'( 2DP1TB *F2
SDF#'( %*F*)D(
? P'4#3B 'F 3'(P'(*TD 3(D2#T 3*(2 7'( ).%., 2DP1TB ).%.
*F2 SDF#'( %*F*)D(
Ad'i!is%ra%ive
The activities carried out at administrative department are as under..
*. 2aily attendance, leave, '2, etc.
. Dnter daily attendance in the %uster (oll of Payroll workers, temporary
workers
+. Dnter 4eave of all employees on the D(P daily through 4otus Fotes and
take follow up for absence and attendance regulari<ation.
". *ttend to /ueries relating to employees attendance, '.T.,'.2., leave, etc.
:. 9age, salary calculation
. Cerify attendance records of Staff, preferment workers and complete
the attendance records through D(P.
+. Process salary of staff through D(P.
". Prepare salary statements, send to accounts to deposit in bank.
? '.T. %onitoring, recording, administrative arrangements
. 3heck, verify G prepare lunch allowance statement of and disburse
payment.
+. 3heck, verify G prepare '.T. Statement of permanent workers.
". 3heck, verify, prepare, disburse occupational allowance payment to
workers
? 3omplete joining formalities and records at the time of joining of a new
employee.
. )et 5(#S, nomination forms and bank account forms filled.
+. 3reate personal file.
". #ssue punch cards, arrange to create master, leave master, email id.
? Process loan, 4T*
? 3omplete separation procedure of leaving employee
. Prepare full G final settlement of left employees, and arrange for
payment
+. 3omplete records like exit interview, relieving letter, 77S
statement, no due clearance, P.7. 9ithdrawal forms, take bake
key, cards, and make entry in all registers and records.
? 3omplete P.7. (elated works of workmen
. prepare monthly P.7. Statement considering any adjustment of last
months, clearance from local accounts, and sent to :aroda of
remittance in bank $by -
th
every month.
+. prepare records for P.7. 9ithdrawal, and send for submission.
? Supervise the payment of wages to all contractor workers
. check the muster roll and payment register for correct entries.
+. 3ertify the payment register regarding payments done.
". 3heck the P.7. 2etails and ensure for timely submission of the P.7.
3hallan in the bank.
=. Preparation of circulars and disciplinary letter in local language.
? 2ay to day administrative expense petty cash
? (ecruitment of temporary workmen. 3reation of master, pay structure in
D(P till 77S
&*-A-C3'ACC01-. $3PA#.)3-.
Financial Decision Areas
SUPPORT
+1PP0#.
RESULTING IN
Shareholder Wealth
Maximiation
!" In#estment Anal$sis
%" Wor&in' (a)ital Mana'ement
*" So+rces and (ost o, F+nds
-" Determination o, (a)ital
Str+ct+re
." Di#idend Polic$
/" Anal$sis o, Ris& and Ret+rns
PRIMAR0 DIS(IPLINES
!" Acco+ntin'
%" Macroeconomics
*" Microeconomics
OT1ER RELATED DIS(IPLINES
!" Mar&etin'
%" Prod+ction
*" 2+antitati#e Methods
8i!a!*e a% Su! Phar'a*eu%i*al I!dus%ries L%d.
The main ,inancial acti#ities o, S+n Pharmace+ticals are handled 3$ head o,,ice in M+m3ai"
The com)an$ has Enter)rise Reso+rce Plannin' 4ERP5 s$stem to handle the ,inancial
acti#ities o, the com)an$" The acco+ntin' de)artment o, Sil#assa )lant handles the
,ollo6in' acti#ities7
? Pa$ment o, Excise 4a,ter ded+ctin' the excise )aid at the time o, )+rchase5"
? Pa$ment o, Income Tax"
? Iss+in' che8+es to the creditors o, the )lant"
? (ross chec&in' o, 3ills and materials"
? (hec&in' the )rices"
? Other mone$ related iss+es"
? Pa$ment o, salar$ thro+'h 3an&"
? 9ee)in' record o, TDS"
? Pa$ment o, TDS"
? Pa$ment o, Pro#ident F+nd"
)A-A43)3-. *-&0#)A.*0- +/+.3)
The main function of %#S is to handle, monitor>store data related to business
procedures of pharma industries different modules have been integrated into single
software. The software is known as #T% $#ntegrated Trading and %anufacturing. where
all modules such as purchase, sales, manufacturing and administration.
Purchase contains all transaction related to purchasing of materials re/uired for making
of products.
Sales contain transaction related to selling >exporting to outside locations when the
product is ready to be dispatched.
%anufacturing related contain transaction related to making of products, preparation of
bill of material, work order, issues receipt, etc.
Similarly administration related to manpower, salary, attendance related activities.
7inance related to collection of payments.
The software is made in power builder and oracle.
6ey role of %#S is to satisfy user re/uirements related to hardware and software
issues giving training imparted to users as to using software for making transactions or
any hardware related problems like printer, keyboard, etc. So basically %#S is a service
department which provides service to users in various other departments. #n providing
data for user in the desired formats used for analysis> planning of business processes.
*lso used for strategies>growth of production related activities.
The other software used in the organi<ation areJ
LOTUS NOTES
#t is used for mailing within the location and also across the locations in the
organi<ations. So that data and messages can be sent and received within seconds.
LOTUS SAMETIME SERVER
#t is a chat facility used within and across locations in organi<ation, another way of
further communication rather than using telephones for the same.
ITM
The #ntegrated Trading G %anufacturing $#T%. automates the business process and
manages the information of business house involved in trading or manufacturing
activities. The %anagement&oriented design of #T% goes hand&in&hand with business
process re&engineering. The activities carried out by the organi<ation should be made
process oriented rather than department oriented. To obtain best result from the usage
of software, the way business is done has to be looked at, from the #T% point of view
and each employeeEs contribution and accountability must be made transparent to the
system. The software complies with the standard business practices followed by the
business houses world over.
#T% expects the user of the system to operate with a minimum business discipline, to
achieve the maximum advantage of the software. The business procedure should be
mapped to the system in a rights way, which re/uire a through knowledge of #T% $all
modules.. Bou can understand #T% by studying the *dministration %anual provided for
each module.
The software is tightly integrated across various modules and functional area of the
organi<ation. *ll the modules works as one system, sharing the information across
departments. 7or example the item master created by the marketing department will be
used by planning, sales and distribution, manufacturing, accounts and costing. *ll the
departments will share the same information generated by each departments. 7or
example sales information entered by the sales department would be used by the
costing department to generate costing information as well as planning department to
create forecast for future months.
)A#93.*-4 $3PA#.)3-.
Sun Pharmaceutical #ndustries 4td., Silvassa plant is only a manufacturing unit i.e.
7ormulation plant and so it does not have marketing department and hence its
marketing has been carried out form 5ead 'ffice %umbai. *bout ;,? of total exports
of Sun Pharmaceutical #ndustries 4td.$#ndia. is been carried out by Silvassa Plant so it
has high turn over and results into key point for marketing.
Six of Sun Pharma s specialty brands feature in the top ",, list of pharma brands
$'() (etail 3hemist *udit, %arch +,,".. Two of the company s new launches feature
among the list of the top ", brands introduced in +,,+. $2ata from '() (etail 3hemist
*udit for +,,+.
*ccording to data from the '() for %arch +,,", Sun Pharma ranked 5th in terms of
new launches "8 new products, value (s.+.,cr, ".5=?%S $last year +nd, "; new
products, (s.8.5!cr. 5.-;? new products %S..
The (s. +-,,,, cr. market for prescription products in #ndia is growing at -?. *s this
market moves from a developing nation market where the larger therapy segments are
those of antibiotics, tonics and vitamins to a more mature market, where lifestyle and
chronic therapy areas are the larger segments $table . , it is likely that specialty areas
will continue to grow at above market growth rates.
#n the #ndian market, there has been increasing competitive interest in chronic therapy
areas, from large #ndian and multinational as well as regional companies. There have
been some signs of growth from multinationals as they begin to introduce new
products in #ndia. 7or some multinational companies, the introduction of new products
in #ndia was fairly close to international launch, unlike their approach earlier, which in
our view indicates a new seriousness from these companies. #ncreasing competition
translates into higher promotional costs across the sector, and impacts margins.
Smaller and regional companies that are not ade/uately covered by the #%S&'()
continued to make their presence felt, and some of these brands made inroads in
larger markets too, particularly for acute therapy products. 9e continue to take the
challenge posed by both these segments multinationals and smaller companies,
seriously.
*cross the group, including subsidiaries, over 5,,,, people work at Sun Pharma.
*bout +,5,, people work in marketing and sales in #ndia, and +-, in international
markets $other than the 1S.. *bout 5,, scientist work in research.
doc_664368174.doc
Hope it will be useful for you guys.
Summer Training
at
SUN PHARMACEUTICAL INDUSTRIES
LTD.
Silvassa
Guided By
Dr. R.S.Shah
Prepared By
Nirav Kariya
Praya Si!h
Neha Si!hal
GIDC Ra""u Shr#$$ R#$$el I!s%i%u%e &$
Ma!ae'e!% S%udies
(api
INDE)
Sr.No. Topic
1 Acknowledgment
2 Company Profile
3 Plant Location
4 Plant Layout
5 Process Layout
6 Production
7 uality control
! "uman #esource $epartment
% &inance'Account $epartment
1( )anagement *nformation +ystem
11 )arketing $epartment
A*+!#,led'e!%
Da%e - ./012012
3e are very %ha!+$ul %# GIDC Ra""u Shr#$$ R#$$el I!s%i%u%e &$ Ma!ae'e!%
S%udies a!d #ur Dire*%#r Dr. R.S.Shah $#r pr#vidi! us a ,#!der$ul su''er
%rai!i! a% Su! Phar'a*eu%i*al i!dus%ries L%d.4 Silvassa.
3e als# %ha!+$ul %# Mr.Pra+ash Raval 5Pla!% Head6 a!d Mr.Pri%e! Nair $#r uidi!
us i! vari#us aspe*%s a!d pr#vidi! us deep pra*%i*al +!#,lede reardi!
'a!ae'e!%. 3e als# %ha!+$ul %# all %he s%a$$ 'e'7ers #$ Su! Phar'a*eu%i*al
I!dus%ries L%d. 8#r spe!di! %heir pre*i#us %i'e i! uidi! us $#r #ur pr#"e*%.
Reards4
Nirav Kariya
Praya Si!h
Neha Si!hal
C#'pa!y Pr#$ile
Sun pharmaceuticals industries ltd. specialty is pharmaceuticals and active pharmaceutical
ingredients. Their brands are prescribed in chronic therapy areas like cardiology,
psychiatry, neurology, gastroenterology, diabetology and respiratory.
They have the same drive for growth that marked our early days. Sun Pharma came into
existence as a startup with just 5 products in !!". #n the time since, they have crossed
several milestones to emerge as a leading pharma company in #ndia, a rank that we have
now been at for more than 5 years. $#%S&'() (etail Store *udit, %arch +,,-.
They have reached leadership in each of the therapy areas that they operate in, and are
rated among the leading companies by key customers. Strengthening market share and
keeping this customer focus remains a high priority area for the company.
#n the post !!- years, we have used a combination of internal growth and ac/uisitions to
drive growth0 important mergers were those of the 1S, 2etroit based 3araco Pharma 4abs
and that of the plant at 5alol which is now 16%5(* and 1S72* approved.
HISTORY
Sun Pharma began in !8" with just 5 products to treat psychiatry ailments. Sales were
initially limited to + states & 9est :engal and :ihar. Sales were rolled out nationally in !85.
Products that are used in cardiology were introduced in !8;, and %onotrate, one of the
first products launched at that time has since become one of our largest selling products.
#mportant products in 3ardiology were then added0 several of these were introduced for the
first time in #ndia.
(eali<ing the fact that research is a critical growth driver, they established their research
center SP*(3 in !!" and this created a base of strong product and process development
skills.
Sun Pharma was listed on the main stock exchanges in #ndia in !!=0 and the (s. 55 crore
issue of a (s. , face value e/uity share at a premium of (s. =,>& was oversubscribed 55
times. The minimum +5? that was re/uired under the regulations then for listing was
offered to the public, the owner family continues to hold a majority stake in Sun Pharma.
They used this money to build a )reenfield site for *P# manufacture, as well as for
ac/uisitions. 7or the ac/uisitions, typically companies or assets that could be turned
around and brought on track were identified.
Their first *P# manufacturing plant was built in Panoli in !!5, for access to high /uality
actives ahead of competition, and to tap the vast international opportunity for specialty
*P#s.
*nother *P# plant i.e. *hmednagar plant, was ac/uired from the multinational 6noll
Pharmaceuticals in !!-, and upgraded for approvals from regulated markets, with
substantial capacity addition over the years. This was the first of several sensibly priced
ac/uisitions, each of which would bring important parts to the long&term strategy.
:y !!;, Sun Pharma@s head/uarter was shifted to %umbai, the commercial capital of the
country. They began on the first of their international ac/uisitions with an initial A;.5 million
investment in 3araco Pharm 4abs, 2etroit. :y +,,,, we had completed 8 ac/uisitions, each
such move adding new therapy areas or offering an entry to important international markets.
* new research center was set up in %umbai for generic product development for the 1S
market. #n #ndia, as new therapy areas were entered into post ac/uisition0 customer
attention, product selection and focused marketing helped us gain a foothold in areas like
orthopedics, gynecology, oncology, etc. 7rom a ranking at "8
th
in !!=, by +,,, we were
ranked 5
th
with a leadership in 8 of the therapy areas that we are present in. The year
+,,, was the year of turnaround at the 1S subsidiary, 3araco, as it began to receive
approvals after successful inspection by the 1S72*. #n 2ecember +,,=, a research center
spread over - acres was inaugurated by the President of #ndia, with special lab space for
drug discovery and innovation.
Milestones
.9:;
Sun Pharma begins operations in 6olkata with 5 psychiatry & based products, first with
+ people and then with a , & employee team. Bear turnover & (s. million. 9ithin a
year, the marketing effort is expanded to cover all eastern states. * compact
manufacturing facility for tablets>capsules is set up at Capi.
.9:/
*dministrative office is set up in %umbai. 3ustomer coverage extends to select cities in
9estern #ndia.
.9:2
%arketing operations are rolled out nation&wide.
.9::
9ith the launch of the brands %onotrate and *ngi<em, the first few cardiology products
are launched. 9e feature for the first time in a market audit by the prescription tracking
company, '() at rank ,;
th
with ,.? market share.
.9:9
The corporate office is shifted to :aroda, in the western state of )ujarat. Products used
in gastroenterology are introduced. Dxports to neighbouring countries begin.
.99.
3onstruction begins at the first research center SP*(3 $Sun Pharma *dvanced
(esearch center., with =-,,,, s/ ft of research space, and investments of almost the
si<e of that yearEs profits. The companyEs turnover is (s. !.;= crore, and market rank is
;,
th
.
.99;
SP*(3, the first research center, is inaugurated by 5is Dxcellency Shri 6. (.
Farayanan, the Cice President of #ndia. *n office is begun in %oscow. Products are
now registered across , markets.
.99<
*fter an #P' in 'ctober, we are listed on the major stock exchanges in #ndia. The
offering is oversubscribed 55 times. * dosage form plant at Silvassa starts production.
%ajor expansion at the plant in Capi is completed. 7or the first time, a brand from the
company, %onotrate, features among the top +5, pharma brands in the #ndian market.
Dxperimenting with a focused marketing approach, a separate division, Synergy, is
carved out to market Psychiatry> Feurology products.
.99=
Sun Pharma first *P# plant at Panoli starts production.
* new division, *<tec, now renamed *<ura, is begun for cardiology products, with a
further reallocation of products across divisions. #nca, a new division to market critical
care medication to intensive care units begins operations. #nternational marketing is
strengthened with offices in 1kraine and :elarus.
.99/
*n *P#&manufacturing unit at *hmednagar, the first of the Sun Pharma ac/uisitions, is
bought from 6noll Pharma,
.992
7irst international ac/uisition of Sun Pharma. *s part of a technology&for&e/uity
agreement, a stake is ac/uired in a generic dosage form manufacturer0 the 2etroit&
based 3araco Pharm 4abs.
T2P4, a company with an extensive product offering $oncology, fertility, anesthesiology,
pain management. is merged with Sun Pharma,
.99:
* basket of brands, which include several in the respiratory>asthma area, are ac/uired
from Fatco Pharma. Sun PharmaEs new formulation plant at Silvassa commences
operations,
.999
(ank moves within the top , in the domestic market. 7or a /uick entry in
ophthalmology, %ilmet 4abs is merged into Sun Pharma.
>111
(anked 5th among all companies in the domestic market on a monthly basis. Pradeep
2rug company, a 3hennai based *P# manufacturer is merged with Sun Pharma.
>11.
* new formulation plant is built in 2arda. This new plant is spread over a 5&acre site with
built up area of +,,,,,&s/. ft. and has been designed and built to comply with
international regulatory re/uirements, such as the 16%5(* and 1S72*.
The erstwhile T2P4 division is renamed Spectra. * new division, *rian, targeting
cardiologists>physicians and diabetologists, is launched.
>11>
7orbes )lobal ranks Sun Pharma in the list of best small +,, companies for +,,+
$turnover less than A5,, million..
Sun Pharma is selected as the best company by Dxpress Pharma Pulse, for overall
performance for +,,+ $in the category * & market share over +.5?.. = manufacturing sites
win the prestigious #2%* awards.
9ork begins on a new (G2 center in %umbai, with 5,,,,, s/. ft. floor area for projects
aimed at the Forth *merican and Duropean markets.
>11;
7orbes )lobal ranks Sun Pharma in the list of the best small +,, companies for +,,"
$turnover less than A5,,million..
Sun Pharma is rated amongst the best&managed companies for +,," across all sectors.
>11<
Sun Pharma ac/uires common stock and options from + large shareholders of 3araco,
increasing stake to over -,? from ==? at a total outlay of about A=+ million.
3onstruction at a formulation manufacturing site at Hammu is completed.
7irst joint venture manufacturing unit, in 2haka, :angladesh is commissioned. This
modern site is spread over +5,,,, s/. ft.
>11=
Sun Pharma buys a plant in :ryan, 'hio, 1S and the business of #3F, 5ungary from
Caleant Pharma.
Sun Pharma ac/uires the intellectual property and assets of *ble 4abs from the 1S
2istrict :ankruptcy court in Few Hersey in 2ecember +,,5.
2ilip Shanghvi, the 3%2, receives the DGB Dntrepreneur of the Bear award in healthcare
and life sciences for +,,5.
Sun Pharma is selected by 7orbes amongst the best +,, companies $sales less than
1S2 billion. in *sia. This is the fourth time in 5 years that the company has been
selected.
The %ally a% %he e!d #$ >11=
? 5 manufacturing plants in " continents
? 5,,, employees
? + 9orld class research centers
? :rand selling in markets worldwide
? * growing presence in the 1S generic market
? #ncreasing research investments
? =,? of sales from international markets
GROUP COMPANIES
Cara*# Phar'a*eu%i*al La7#ra%#ries
:ased in 2etroit, %ichigan, 3araco develops and manufactures generic pharmaceuticals
and markets them throughout the 1nited States. The corporationEs present portfolio
consists of a number of products in various strengths and package si<es. The
corporationEs drugs relates to a variety of therapeutic segments.
3aracoEs manufacturing facility and executive offices were constructed in !!,
Su! Phar'a*eu%i*al I!dus%ries I!*.
Sun Pharmaceutical #ndustries #nc is a %ichigan 3orporation and a wholly owned
subsidiary of Sun Pharmaceutical #ndustries 4td, #ndia. The company distributes
pharmaceutical products throughout the 1nited States and around the world.
#n the second half of +,,=, Sun Pharma ac/uired the trademarks, manufacturing know&
how and other intellectual property of certain pharmaceutical products from 9omenEs
7irst 5ealth care, #nc,
#n 2ecember +,,=, the company entered into a manufacturing and supply agreement
with 3araco Pharm 4abs, under the terms of this agreement, 3araco manufactures and
supplies the products to the company. #n Hanuary +,,5, the company entered into a
distribution and sale agreement with 3araco. 1nder the agreement, 3araco distributes
and sells these products using its business organi<ation, management personnel, and
distribution set up.
Su! Phar'a*eu%i*al 5Ba!ladesh6
Sun Pharmaceutical $:angladesh. is a private limited company incorporated in %arch
+,, under the 3ompanies *ct !!=. This company was formed jointly with Sun
Pharma, 3ity 'verseas 4td, a company incorporated in :angladesh and Sun Pharma
)lobal #nc, a company incorporated under the laws of the :ritish Cirgin #slands. The
company began commercial operations in 'ctober +,,=. The company owns and
operates a pharmaceutical factory and makes pharmaceutical products that are sold in
the local market.
ACQUISITIONS
? Tamil Fadu 2adha Pharmaceuticals
*c/uisition, !!;
? )ujarat 4yka 'rganics 4td.
D/uity stake !!-, %erged !!!
? %H Pharmaceuticals 4td.
D/uity stake, !!-0 merged with Sun Pharma in +,,+&,"
? 3araco
Subsidiary&initial e/uity stake !!;, incremental stake increases !!;&+,,",
larger stake buyout +,,=
? :rands from Fatco Pharma
:rand buyout, !!8
? %ilmet 4abs
*c/uisition, !!!
? Pradeep 2rug 3ompany 4td
*c/uisition, +,,,
? Phlox Pharma
%erged +,,=
? Fiche brands purchased from 9omenEs 7irst 5ealth care
+,,=
?
? #3F, 5ungary $+,,5. and a manufacturing plant in :ryan, 'hio
+,,5
? *ble 4abs
*ssets only, 2ecember +,,5
MANUFACTURING
9ith world class technology and a team of strong professionals, we have built sites and
systems that meet the most stringent international manufacturing standards. Dxpert
/uality teams ensure that systems and processes remain in compliance with the latest
standards. * number of our plants hold approvals from the 1S72* and the 16 %5(*.
*P#s and 2osage forms are made in 5 sites across #ndia, 1S, 5ungary and
:angladesh.
FORMULATION
Sun PharmaEs specialty product range features solid oral dosage forms $tablets,
capsules., injections, nasal sprays, aerosols, dry powder inhalers, ophthalmic
preparations, creams and ointments as well as technically complex preparations like
melt tabs, liposome based products, depot preparations and time release > controlled
release preparations.
API
Sun Pharma make specialty *P# at large world class sites with multi reaction and multi
capacity flexibility. #n all, the total reaction capacity is over ++, 64>year.
5ungarian plant is part of a recent ac/uisition, that of the company #3F 5ungary,
formerly known as *lkaloida. This is one of the few sites worldwide authori<ed to make
controlled substance *P#s.
Sun PharmaEs plants at Panoli and *hmednagar.
*ll its plants are large, well&designed and comply with international re/uirements.
?UALIT@ P&LIC@
Sun Pharma have put in place the infrastructure and procedures to support a stringent
/uality policy. *ll their systems are well documented and are implemented by an expert
trained staff with a line of reporting that is independent of manufacturing.
They are committed to ensure that every product we manufacture and distribute meets
with and conforms over its shelf life to internationally accepted standards of /uality,
purity, efficacy and safety.
*t each manufacturing site, the latest analytical instruments and tightly monitored /uality
assurance and /uality control systems ensures consistent /uality of Sun Pharma
products.
The /uality team at each manufacturing site is guided by a 3orporate Iuality 1nit $3I1..
This 3I1 has members from /uality assurance, /uality engineering, /uality control, and
regulatory affairs. 3I1 regularly updates location&based /uality representatives on new
regulatory practices and monitors the /uality of documentation in order to comply with
changing international re/uirements.
EN(IR&NMENTAL P&LIC@
%anufacturingJ 3onsistently producing to the worldEs re/uirements.
3oncern for the environment and safety.
Dach of our manufacturing sites is fully e/uipped with facilities to handle waste and
minimi<e environmental contamination. *t Sun Pharma, a concern for safety and the
environment is part of our plans right from the drawing board. 9e pay close attention to
preventing and reducing pollution, avoiding accidents and conserving resources.
Research and Development: Building a strong research base
*t Sun Pharma, we are committed to world class research to develop the latest
medicines and bring them to market for patient benefit at a reasonable cost. 'ur (G2
efforts help us develop a product basket, including products that have complex
technologies, for the international markets. 7ocused development in defined areas and
interest in applying innovative technologies are key to our efforts.
Sun Pharma first research center, Sun Pharma *dvanced (esearch 3enter $SP*(3.,
was set up in !!" in :aroda in the western state of )ujarat in #ndia. The work done
here was instrumental for the rapid growth at Sun Pharma. Starting from a small base,
the infrastructure at this initially "+,,,, s/ ft research center was used to streamline
product development to bring to market on an average ", formulations and 8&, new
*P# every year.
#n +,,=, a new research campus with areas for process > product development as well
as drug discovery and delivery systems went on stream in :aroda. 5is Dxcellency, 2r. *
P H *bdul 6alam, the 5on. President of #ndia, formally inaugurated this research center
in a glittering ceremony in 2ecember +,,=.
This -&acre campus with +5,,,,, s/ ft research area offers space for world&class
pharmaceutical research0 both for complex generics and new&to&the&world drug
discovery.
#n the first phase of innovation, a drug discovery initiative is taking shape in " specific
therapy areas and across = drug delivery system platforms. These projects, on
successful completion, can offer strong potential across international markets. 5ence
these call for focus. The intellectual property that we build from these projects can one
day earn revenue streams globally. #n view of this opportunity and recogni<ing that
innovation is a uni/ue business & #nnovative (G2 is proposed to be demerged into a
separate company.
* second research center was set up in !!; in %umbai to develop generics for the
developed markets. This center has developed products for 3araco & most of the
products that are marketed by our 1S subsidiary were developed by this team.
The current research commitment is between &+? of the companyEs turnover and
weEve put in a total of (s. -,,, million for research since !!". Their approach to
research has been incremental starting with the simple and moving on to the more
complex. Sun Pharma began with simpler dosage forms, and then moved on to novel
drug delivery systems and complex *P#. *cross areas, =+ patents have been received
and another =++ patents are awaited. Dvery year, Sun Pharma typically bring about =,
new products to the #ndian market, scale up +, *P#, develop and file for +, plus *F2*s
for the 1S and 8&, 2%7s for 1S > Durope.
P4*FT 4'3*T#'F
Location and Surroundings
L#*a%i#!
? Pharmaceutical formulation plant should not be in a chemical <one.
? Feighbouring unit should not generate any air, water or noise pollution, which can
affect the man, material, machinery and the product /uality of the formulation plant.
Surr#u!di!s
? Protection is re/uired against the entry of insects, rodents and other pests0 in
particular, the stray dogs and cats must be prevented.
? The surroundings must always present a clean and good appearance0 obvious signs
of neglect or lack of maintenance such as broken windows, peeling paint,
accumulation of debris, untended gardens and so on, give rise to serious doubts about
good manufacturing practices.
? :uilding should have ade/uate garden, but not too near to the walls of the main
building.
? Security office should have visibility from all sides.
? Provision of instructions $no smoking board, etc.
? 4ay&out of premises.
? *larm for any emergency
? 7irst aid box
? 2isplay of contact number of head of different authority $factory inspector, police, fire
brigade, hospital, collector, plant head, etc.
? Separate administration block
? 1tility block $generator house, air compressor house, boiler house.
? Solvent storage
? DTP plant
? Scrap yard
? Transformer house should be provided
? 1nderground tank should be avoided and if re/uired than it should be constructed of
round shape and the top of the tank should be at road level, so that fire brigade van
can stand on it.
? Street shoes cleaning facility specially for monsoon season so that mud will not come
with shoes in area.
? *de/uate parking facility for vehicles.
? Storage tank for diesel, etc at safe place.
*ny building used in manufacturing process, packing or holding of a drug product, shall
be of J
? Suitable si<e
? 3onstruction
? 4ocation to facilitateJ
?
• 3leaning
• %aintenance
• Proper operation
:uilding should have ade/uate space for the placement of e/uipment and materials to
prevent0
? %ix&ups
? 3ontamination
? The design should permit effective communication and supervision.
? 2esign of the building should be such that it provides unidirectional flow of
materials to reduce any chances of confusion and contamination.
? 3onventional designs feature such as a corridor running along the length of the
building with rooms, cubicles, halls and other areas opening in to it.
? The merit of this design is the isolation of manufacturing operations from non&
related activities and confinement of the movement of people to a common
passage.
1nit processes for a product should be carried out in the areas physically segregated
from one another with the result that a batch in process moves from one area to another
through hatch provided between adjacent rooms to facilitate the movement of in&process
material in controlled $temperature, humidity and pressure differential. area and will
never enter into corridor.
PLA-. LA/01.
4ayout of the building should be off vertical structure for gravity feeding in which the
material movement is in unidirectional flow and which reduces material loading and
unloading.
The above mentioned design consists of the following featuresJ
? (aw material store, dispensing booth, staging area for storage of dispensed (.%.,
sifting, milling operation with washing facility should be at second floor of the building.
? Sifting room is designed as one e/uipment one area with independent dust collector
unit and air handling system with terminal 5DP* filter and S.S. stand for utensil with
hanger for gloves is re/uired in the area
? 'ne S.S. connecting pipe with sanitary fitting can be attached with bottom discharge of
#P3 and charging point of (%) keeping lid closed
? Sifted material collected in #P3 is directly charged in to (%).
? Similarly milling operation can be done in independent area and facility is to be
provided as with sifter room.
? *rea for granulation, blending, '5( and Iuality 3ontrol laboratory should be at first
floor.
? (%) room should have separate *.5.1. and facility to run mercury lamp and sodium
vapour lamp.
? 1tilities like potable water, steam, non&lubricated area, purified water and hot air should
be provided with drain point facility.
? The material flows from sifting and milling area to (%) through raw material transfer
pipe.
? 7rom (%) to blending the material moves through hatch provided between adjacent
rooms.
? Powder transfer system using vacuum as a principle is acceptable to avoid human
touch in blending area.
? The lubricated granules are to be transferred from '5( $over head room. located at
the first floor in front of granulation area by the raw material transfer pipe to the
compression machine located below the '5(.
Process Layout
PRODUCTION
Were House
1nder warehouse there are three departments. They areJ
(aw %aterial Store $(.%.S.
Purchase %aterial Store $P.%.S.
nded Store (oom $:.S.(.Ra, Ma%erial S%#re
The main work of (.%.S is to dispense raw material to production department. The
following areas are covered in this department areJ
. 4oading and unloading platform
+. Iuarantine area
". Sampling area
=. 2ispensing area
5. (ejected area
-. 3old storage facility
;. Potent drug storage
8. (eceiving bay
Pa*+ai! Ma%erial S%#re
The main work of this department is to dispense packing material to packing
department..
The following function are being carried in this department areJ
. To receive packing material
+. To label received material
". To arrange for labeling of material
=. To store material as per status of material
5. To dispense> issue material
-. To maintain /uality of store material
;. To maintain physical stocks as per D(P systemEs stock
8. To identify shortage and coordinate for procurement as per production plan.
B#!ded S%#re R##'
The main work of this department is to receipt, handling, storage of finished goods and
dispatch of finished goods.
The main function of this department areJ
? (eceipt of finished goods from packing
? %aintaining documents related to excise
? %onitoring of modat of input and P4*
? 4egal formality and documentation with excise authority
? %aintaining of finished goods stock and documentation
? 2ispatch and documentation
? %aintaining stock statement Cs. physical stock
Pr#du*%i#! Depar%'e!% C#!sis%s &$
? )ranulation
? 3ompression
? 7
> 3oating? 2P#> 3apsule
? Packing
Granulation
)ranulation is a process of getting granules from fine powder or preferably be reduce
to the same particles si<e, since particles of different si<e will have a tendency to get
layered during mixing.
Gra!ula%i#! is d#!e 7y
. 9et )ranulation
+. 2ry )ranulation
EAuip'e!% used are
? Cibro Sifter
? 3lit mill
? (apid %ixer )ranulator
? 7luidi<ed :ed 2ryer
? Steam Hacketed 6ettle
? :lender
Pr#*ess
S#7T#F) *F2 %#44#F)
23. 4#A-1LA.*0-
5 )*6*-47
)*LL*-4 0& +L14+
$#/ 4#A-1LA.*0-
&*-AL 8L3-$*-4
5L18#*CA.*-47
Compression
#t is carried out after granulation.
3ompression is a property of forming stable mass when press is applied.
3ompression is achieved by taking granules in a die and compressing them between a
set of two punches.
EAuip'e!%s-
(otary tablet compression machine. There are six machines of compression in sun
pharmaceutical
exJ "5 Station machine
"; station machine
=5 station machine
Pr#*ess #$ *#'pressi#!
4oad granules in hopper$top of machine.
*djust machine for
? 3ompression weight
? 5ardness
? Thickness
? 2isintegration time
K 2iscard initial + rounds of tablet
(est all the tablets are kept for inspection
$to find out and remove defective tablets,
tablet inspection machine is used..
FBP/ Coating
3oating is done to improve elegance and organoleptic /uality.
%ainly coating is done toJ
. %ask the taste, color and odour of drugs.
+. To provide physical and chemical protection for drugs.
". To control the release of drug.
=. To protect the drug from gastric environment of stomach with acid resistance
enteric coating.
5. To improve particular aligance by use of special color.
DPI/CAPSULE
3apsule are the solid dosage form in which the drug substance are enclosed within
either a hard or soft soluble shell usually forms from gelatin.
QUALITY CONTROL
Iuality dept. is a centrali<ed department of Sun pharma. #t consists of two sub dept.J
? Iuality 3ontrol
? Iuality *ssurance
Iuality control looks upon /uality of raw materials and formulation whereas /uality
assurance looks upon dispatch material.
'ver all in /uality dept. there are about =, staff members and one senior manager.
*mong =, members +; is in I3 dept. and " in I* dept.
Ma!ae'e!% Pla!!i!
*ll members in this dept are been divided according to the department of sun pharma,
for e.g. (%S dept., P%S dept., etc. Dmployees work according to their job
responsibility. Dvery pharma material that enters or exit from sun pharma is being
checked and approved by I3 and I* dept. for e.g. (aw material enter in plant is
being first sampled by I3 and then approved for further process. Similarly for other
departments the procedure carried same and hence, each and every employee of I3
and I* is being divided according departments each and every procedure followed
between the dept. is being controlled and coordinated by D(P system.
To achieve the objective I3 department functions as follows
? To plan and manage all the, activity of I3.
? To coordinate with manufacturing department in controlling their process and
products at every stage of production to meet the established specification.
? To coordinate for development of specification analytical procedure in
coordination with I* dept. and (G2 department.
? To review the ade/uacy and relevance of specification and analytical procedure
in coordination with I* and (G2.
? To coordinate technical audit of I3 lab.
? To determine the analytical /uality system are yielding the highest /uality
information and to ensure the calibration of instruments and servicing as per
schedule.
"1)A- #3+01#C3
$3PA#.)3-.
#t consists of two sub departmentsJ
? Personal department
? *dministrative department
PERSONAL DEPARTMENT
This department consists of process like training and development, recruitment and
selection, performance appraisal, policy implementation, compensation, etc.
Re*rui%'e!% a!d sele*%i#!
The procedure of recruitment and selection is being carried out as followJ
#f there is any new vacancy or vacant position a %P( 7orm i.e. manpower re/uisition
form is being filled by department head and then sends to head office in %umbai to get
approval of it. #f %P( is being approved than as the profile re/uirement an
advertisement is issued. *nd the se/uence goes as followJ
? Pri#r &$$er
? *pplication > resume receive
? 3all letter for preliminary interview
? Personal information form filling on the day of interview
? (eturn test on respective subjects
? Preliminary interview assessment sheet filled by panel member
? 3all letter for final interview
? 7inal interview assessment sheet filled by plant head
? 2ocument
• Proof of date of birth
• %ark sheet of post graduation, graduation, +
th
, !
th
and additional
/ualification if any.
#f the person being selected his documents is send to head office %umbai and on the
basis that a joining offer letter is being issued from head office %umbai.
? Duri! &$$er
? %edical report
? Signing offer letter
? Day #$ "#i!i!
? (elieving letter from previous employer > copy of resignation letter
? 9ork experience certificate
? 7orm + i.e. )ratuity form $photo copy.
? 7orm f i.e. provident fund
? 5(#S 7orm
? *ppointment letter
? #n the course of employment
? 4etter of probation
? 4etter of conformation
? #ncrement letter
? 'ffice order
*t last the employee is being added to D(P system and date of master entry and pay
roll entry in D(P is being recorded. *nd the employee is being provided with an intra
mail e&mail #d.
Training and developmentJ
Training in sun pharma is being carried out according to the procedure and format
mention in S'P $Standard 'perating Procedure..
Type #$ %rai!i! *arried #u% a% Su! phar'a is
? Dxternal Training
? 3lass room Training
? 'n the job training
? induction training
E)TERNAL TRAINING
#n external training a person is being nominated as per the information from various
agencies on consultation department head as per the information. The necessary
arrangement to attain the external training is being made as per the re/uirement and
there after training is being maintained for e.g. 'n ++
nd
of Hune +,,; %r. Sujoy
3haudhry has been invited to give training on the topic assertiveness and team
building.
CLASSR&&M TRAINING
* training schedule for the entire department is being prepared and circulated to the
department head. #f the schedule is finali<ed then training aids are being prepared and
training program is being conducted. There after training record is being maintained.
'n the basis of classroom training a evaluation is done for competence and
effectiveness.
&N THE B&B TRAINING
#n this training a competent person organi<es on job training to concern person and
demonstrate the actual operation. This training is being given by the department head
to staff members or supervisors or even by the consulted to whole department.
INDUCTI&N TRAINING
This training is being carried out for new employee on the first day of joining. There is
an induction form which is being filled by new employee which contains sufficient detail
about him. There after he has been introduced to each an every department head and
explain a brief profile of Sun Pharma.
P&LIC@ IMPLEMENTATI&N
There are several policies designed by 5.'. 9hich has been commonly followed
by all the plants of Sun Pharmaceutical #ndustries 4td. Some of the policies followed in
SP#4 are as follows..
? P'4#3B 'F 4D*CD
? 1SDS '7 3'%P*FB P('213T
? P'4#3B 'F 3*( 4'*F T' SDF#'( %*F*)D( *F2 2DP1TB
%*F*)D(
? P'4#3B 'F TD4DP5'FD 7*3#4#TB 7'( %*F*)D(
? P'4#3B 'F T(*FSP'(T*T#'F 7'( ST*77
? PD(S'F*4 *33#2DFT #FS1(DF3D P'4#3B
? P'4#3B 'F T'1( *2C*F3D
? P'4#3B 'F 5'SP#T*4#L*T#'F
FD7#TS? P'4#3B 'F 2(DSS (D#%:1(DSD%DFTS 7'( 2DP1TB *F2
SDF#'( %*F*)D(
? P'4#3B 'F 3'(P'(*TD 3(D2#T 3*(2 7'( ).%., 2DP1TB ).%.
*F2 SDF#'( %*F*)D(
Ad'i!is%ra%ive
The activities carried out at administrative department are as under..
*. 2aily attendance, leave, '2, etc.
. Dnter daily attendance in the %uster (oll of Payroll workers, temporary
workers
+. Dnter 4eave of all employees on the D(P daily through 4otus Fotes and
take follow up for absence and attendance regulari<ation.
". *ttend to /ueries relating to employees attendance, '.T.,'.2., leave, etc.
:. 9age, salary calculation
. Cerify attendance records of Staff, preferment workers and complete
the attendance records through D(P.
+. Process salary of staff through D(P.
". Prepare salary statements, send to accounts to deposit in bank.
? '.T. %onitoring, recording, administrative arrangements
. 3heck, verify G prepare lunch allowance statement of and disburse
payment.
+. 3heck, verify G prepare '.T. Statement of permanent workers.
". 3heck, verify, prepare, disburse occupational allowance payment to
workers
? 3omplete joining formalities and records at the time of joining of a new
employee.
. )et 5(#S, nomination forms and bank account forms filled.
+. 3reate personal file.
". #ssue punch cards, arrange to create master, leave master, email id.
? Process loan, 4T*
? 3omplete separation procedure of leaving employee
. Prepare full G final settlement of left employees, and arrange for
payment
+. 3omplete records like exit interview, relieving letter, 77S
statement, no due clearance, P.7. 9ithdrawal forms, take bake
key, cards, and make entry in all registers and records.
? 3omplete P.7. (elated works of workmen
. prepare monthly P.7. Statement considering any adjustment of last
months, clearance from local accounts, and sent to :aroda of
remittance in bank $by -
th
every month.
+. prepare records for P.7. 9ithdrawal, and send for submission.
? Supervise the payment of wages to all contractor workers
. check the muster roll and payment register for correct entries.
+. 3ertify the payment register regarding payments done.
". 3heck the P.7. 2etails and ensure for timely submission of the P.7.
3hallan in the bank.
=. Preparation of circulars and disciplinary letter in local language.
? 2ay to day administrative expense petty cash
? (ecruitment of temporary workmen. 3reation of master, pay structure in
D(P till 77S
&*-A-C3'ACC01-. $3PA#.)3-.
Financial Decision Areas
SUPPORT
+1PP0#.
RESULTING IN
Shareholder Wealth
Maximiation
!" In#estment Anal$sis
%" Wor&in' (a)ital Mana'ement
*" So+rces and (ost o, F+nds
-" Determination o, (a)ital
Str+ct+re
." Di#idend Polic$
/" Anal$sis o, Ris& and Ret+rns
PRIMAR0 DIS(IPLINES
!" Acco+ntin'
%" Macroeconomics
*" Microeconomics
OT1ER RELATED DIS(IPLINES
!" Mar&etin'
%" Prod+ction
*" 2+antitati#e Methods
8i!a!*e a% Su! Phar'a*eu%i*al I!dus%ries L%d.
The main ,inancial acti#ities o, S+n Pharmace+ticals are handled 3$ head o,,ice in M+m3ai"
The com)an$ has Enter)rise Reso+rce Plannin' 4ERP5 s$stem to handle the ,inancial
acti#ities o, the com)an$" The acco+ntin' de)artment o, Sil#assa )lant handles the
,ollo6in' acti#ities7
? Pa$ment o, Excise 4a,ter ded+ctin' the excise )aid at the time o, )+rchase5"
? Pa$ment o, Income Tax"
? Iss+in' che8+es to the creditors o, the )lant"
? (ross chec&in' o, 3ills and materials"
? (hec&in' the )rices"
? Other mone$ related iss+es"
? Pa$ment o, salar$ thro+'h 3an&"
? 9ee)in' record o, TDS"
? Pa$ment o, TDS"
? Pa$ment o, Pro#ident F+nd"
)A-A43)3-. *-&0#)A.*0- +/+.3)
The main function of %#S is to handle, monitor>store data related to business
procedures of pharma industries different modules have been integrated into single
software. The software is known as #T% $#ntegrated Trading and %anufacturing. where
all modules such as purchase, sales, manufacturing and administration.
Purchase contains all transaction related to purchasing of materials re/uired for making
of products.
Sales contain transaction related to selling >exporting to outside locations when the
product is ready to be dispatched.
%anufacturing related contain transaction related to making of products, preparation of
bill of material, work order, issues receipt, etc.
Similarly administration related to manpower, salary, attendance related activities.
7inance related to collection of payments.
The software is made in power builder and oracle.
6ey role of %#S is to satisfy user re/uirements related to hardware and software
issues giving training imparted to users as to using software for making transactions or
any hardware related problems like printer, keyboard, etc. So basically %#S is a service
department which provides service to users in various other departments. #n providing
data for user in the desired formats used for analysis> planning of business processes.
*lso used for strategies>growth of production related activities.
The other software used in the organi<ation areJ
LOTUS NOTES
#t is used for mailing within the location and also across the locations in the
organi<ations. So that data and messages can be sent and received within seconds.
LOTUS SAMETIME SERVER
#t is a chat facility used within and across locations in organi<ation, another way of
further communication rather than using telephones for the same.
ITM
The #ntegrated Trading G %anufacturing $#T%. automates the business process and
manages the information of business house involved in trading or manufacturing
activities. The %anagement&oriented design of #T% goes hand&in&hand with business
process re&engineering. The activities carried out by the organi<ation should be made
process oriented rather than department oriented. To obtain best result from the usage
of software, the way business is done has to be looked at, from the #T% point of view
and each employeeEs contribution and accountability must be made transparent to the
system. The software complies with the standard business practices followed by the
business houses world over.
#T% expects the user of the system to operate with a minimum business discipline, to
achieve the maximum advantage of the software. The business procedure should be
mapped to the system in a rights way, which re/uire a through knowledge of #T% $all
modules.. Bou can understand #T% by studying the *dministration %anual provided for
each module.
The software is tightly integrated across various modules and functional area of the
organi<ation. *ll the modules works as one system, sharing the information across
departments. 7or example the item master created by the marketing department will be
used by planning, sales and distribution, manufacturing, accounts and costing. *ll the
departments will share the same information generated by each departments. 7or
example sales information entered by the sales department would be used by the
costing department to generate costing information as well as planning department to
create forecast for future months.
)A#93.*-4 $3PA#.)3-.
Sun Pharmaceutical #ndustries 4td., Silvassa plant is only a manufacturing unit i.e.
7ormulation plant and so it does not have marketing department and hence its
marketing has been carried out form 5ead 'ffice %umbai. *bout ;,? of total exports
of Sun Pharmaceutical #ndustries 4td.$#ndia. is been carried out by Silvassa Plant so it
has high turn over and results into key point for marketing.
Six of Sun Pharma s specialty brands feature in the top ",, list of pharma brands
$'() (etail 3hemist *udit, %arch +,,".. Two of the company s new launches feature
among the list of the top ", brands introduced in +,,+. $2ata from '() (etail 3hemist
*udit for +,,+.
*ccording to data from the '() for %arch +,,", Sun Pharma ranked 5th in terms of
new launches "8 new products, value (s.+.,cr, ".5=?%S $last year +nd, "; new
products, (s.8.5!cr. 5.-;? new products %S..
The (s. +-,,,, cr. market for prescription products in #ndia is growing at -?. *s this
market moves from a developing nation market where the larger therapy segments are
those of antibiotics, tonics and vitamins to a more mature market, where lifestyle and
chronic therapy areas are the larger segments $table . , it is likely that specialty areas
will continue to grow at above market growth rates.
#n the #ndian market, there has been increasing competitive interest in chronic therapy
areas, from large #ndian and multinational as well as regional companies. There have
been some signs of growth from multinationals as they begin to introduce new
products in #ndia. 7or some multinational companies, the introduction of new products
in #ndia was fairly close to international launch, unlike their approach earlier, which in
our view indicates a new seriousness from these companies. #ncreasing competition
translates into higher promotional costs across the sector, and impacts margins.
Smaller and regional companies that are not ade/uately covered by the #%S&'()
continued to make their presence felt, and some of these brands made inroads in
larger markets too, particularly for acute therapy products. 9e continue to take the
challenge posed by both these segments multinationals and smaller companies,
seriously.
*cross the group, including subsidiaries, over 5,,,, people work at Sun Pharma.
*bout +,5,, people work in marketing and sales in #ndia, and +-, in international
markets $other than the 1S.. *bout 5,, scientist work in research.
doc_664368174.doc